Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Amelubant in Cystic Fibrosis
NCT02269189Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2002
- Primary completion
- Nov 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of amelubant in cystic fibrosis (CF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Changes from baseline in physical examination, Number of patients with clinically relevant findings in vital signs and 5 more. Started Apr 2002; status: completed.
02
Drugs
amelubant
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02269189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269189.